A phase 1/11 study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas
1997

Study of LCF Chemotherapy in Unknown Primary Cancer

Sample size: 40 publication Evidence: moderate

Author Information

Author(s): A Rigg, D Cunningham, M Gore, M Hill, M O'Brien, M Nicolson, J Chang, M Watson, A Norman, A Hill, J Oates, H Moore, P Ross

Primary Institution: The Royal Marsden Hospital, Institute of Cancer Research

Hypothesis

The study aims to determine the maximum tolerated dose of 5-FU in combination with leucovorin and carboplatin for patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.

Conclusion

The study found that the maximum tolerated dose of 5-FU in the LCF regimen was 370 mg/m², with an overall objective response rate of 25%.

Supporting Evidence

  • The maximum tolerated dose of 5-FU was determined to be 370 mg/m².
  • 25% of patients had an objective response, including one complete response and nine partial responses.
  • The median survival for all patients was 7.8 months.
  • Patients reported symptomatic improvements with the LCF regimen.

Takeaway

Doctors tested a new cancer treatment on 40 patients and found that it helped some of them feel better and live longer.

Methodology

The study involved 40 patients with metastatic carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas, treated with a regimen of leucovorin, carboplatin, and 5-FU, with dose escalation based on toxicity.

Limitations

The study had a small sample size and included patients with varying performance statuses.

Participant Demographics

{"median_age":59,"age_range":"31-74","sex_distribution":{"male":23,"female":17}}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication